Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

TDC'er til behandling af lægemiddelresistent epilepsi

16. september 2026 opdateret af: Moises Aguilar Domingo, Spanish Foundation for Neurometrics Development

Transkraniel jævnstrømsestimulering til behandling af lægemiddelresistent epilepsi hos børn

Epilepsy is the fourth overall neurologic disorder, regardless of age and gender, affecting more than 50 million people worldwide. Modern epidemiological studies indicate that the global annualized cumulative incidence ranges between 42.8 and 67.8 new cases per 100,000 people each year, with figures scaling up to 139 per 100,000 in low- and middle-income regions. A community-based study conducted in France concluded that up to 22.5% of patients could be classified as presenting drug-resistant epilepsy. This group presents significant hazards such as an increased risk of death, injuries, psychosocial dysfunction, and a reduced quality of life.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The International League Against Epilepsy (ILAE) defines drug-resistant epilepsy as follows: A failure of adequate trials of two (or more) tolerated, appropriately chosen, appropriately used antiepileptic drugs (whether administered as monotherapies or in a combination) to achieve freedom from seizures. This significant amount of patients is the drive to develop different approaches in order to offer alternatives for control.In this regard, non-invasive brain stimulation protocols lead the way, since the pathophysiological substrate of epilepsy is an enhanced cortical excitability, leading to paroxysmal depolarization shifts, an enhanced probability of high-frequency and hypersynchronous activity of small neuronal networks, and the abnormal spreading of this pathological activity along cortico-cortical and cortico-subcortical neuronal connections.Transcranial direct current stimulation (tDCS) consists of short-lasting electric stimulus delivered to specific brain regions. When delivered repeatedly, it generates long-lasting cortical excitability shifts through mechanisms resembling long-term depression (LTD). In this study, cathodal tDCS (c-tDCS) is utilized to apply a hyperpolarizing current directly over the primary epileptogenic focus, aiming to suppress pathological network activity and reduce seizure frequency in pediatric patients.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

150

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 10 år (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Pediatric patients aged between 4 and 6 years at the time of screening.
  • Formally diagnosed with drug-resistant focal epilepsy according to the International League Against Epilepsy (ILAE) criteria (failure of adequate trials of two or more tolerated, appropriately chosen, and appropriately used antiepileptic drug regimens).
  • Experiencing a baseline frequency of at least 3 clinical seizures per week, documented via a reliable prospective seizure diary kept by parents or caregivers.
  • Patients whose legal guardians are willing and able to provide written informed consent, and patients who can provide assent when age-appropriate.

Exclusion Criteria:

  • Presence of metallic implants in the brain or skull (e.g., surgical clips, cochlear implants) near the site of electrode placement.
  • History of severe cardiac arrhythmias, unstable cardiovascular disease, or baseline pacemaker dependent, which may compromise safety during Heart Rate Variability (HRV) monitoring.
  • Progressive neurological disorders, neurodegenerative diseases, or active brain tumors.
  • Recent changes in antiepileptic drug (AED) dosages or types within the 4 weeks prior to baseline screening.
  • Any active skin lesions, inflammation, or structural cranial abnormalities at the target electrode site that prevent safe application of the tDCS pads.
  • Current participation in another clinical trial involving investigational drugs or neurostimulation devices.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental: Active c-tDCS Group

A cohort of 50 pediatric patients with drug-resistant focal epilepsy experiencing at least 3 seizures per week. Participants receive active cathodal transcranial direct current stimulation (c-tDCS) targeted over the primary epileptogenic focus. Digital electroencephalography (EEG) utilizing a 19-channel montage is performed immediately before and after the intervention period. Treatment efficacy on psychosocial outcomes is evaluated using the Quality of Life in Epilepsy Inventory for Adolescents/Children (QOLIE-31) questionnaire.

Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.

Andre navne:
  • Placebo
  • tDCS
  • Ikke-invasiv elektrisk stimulering af hjernen
Eksperimentel: Device: Active Cathodal tDCS

Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 35 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.

Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.

Andre navne:
  • Placebo
  • tDCS
  • Ikke-invasiv elektrisk stimulering af hjernen
Sham-komparator: : Placebo Comparator: Sham tDCS Group

A control cohort of 50 pediatric patients with drug-resistant focal epilepsy experiencing at least 3 seizures per week. Participants undergo the identical procedural, preparation, and 19-channel EEG monitoring protocols before and after the intervention as the experimental group, but receive inactive sham (placebo) stimulation. Quality of life tracking is assessed via the QOLIE-31 questionnaire.

Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.

Andre navne:
  • Placebo
  • tDCS
  • Ikke-invasiv elektrisk stimulering af hjernen

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Weekly Seizure Frequency
Tidsramme: Baseline and Week 24

Assessment of patient-reported quality of life. The total score ranges from 0 to 100 points, where higher scores indicate a better quality of life. This scale will be evaluated as a single independent outcome measure. BaselineF LIFE IN EPILEPSY - QOLIE-31.

Baseline and Week 24
Heart Rate Variability (HRV) Changes
Tidsramme: Baseline and Week 24

To evaluate cardiac safety, specific parameters will be extracted and analyzed from standard 12-lead ECG recordings. The assessed components will explicitly include: Heart Rate (bpm), PR interval (ms), QRS complex duration (ms), QT interval (ms), and corrected QT interval (QTc, ms) using Fridericia's formula

Baseline and Week 24
Change from Baseline in Seizure Frequency
Tidsramme: Baseline and Week 24

Evaluation of efficacy based on the change in seizure frequency. This metric will assess the number of observable seizures per 28-day period (seizures/28 days), as documented by patient/caregiver diaries, comparing the baseline phase to the final 4 weeks of the treatment period (up to Week 24).

Baseline and Week 24
Change from Baseline in Vital Signs
Tidsramme: Baseline and Week 24

Evaluation of clinical safety through the assessment of vital signs. The specific metrics to be evaluated independently as continuous variables include: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Heart Rate (beats per minute), and Body Temperature (°C).

Baseline and Week 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Brain Electrical Activity via Electroencephalogram (EEG)
Tidsramme: Baseline and Week 24

Neurophysiological changes and treatment efficacy will be quantified using quantitative EEG (qEEG) analysis. The evaluation will precisely assess changes in absolute and relative power spectral density across the following frequency bandwidths: Delta (0.5-4 Hz), Theta (4-8 Hz), Alpha (8-12 Hz), and Beta (12-30 Hz). Additionally, the hourly frequency of epileptiform discharges (spikes and sharp waves) will be quantified to assess seizure susceptibility.

Baseline and Week 24

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Kessler Foundation Neglect Assessment Process
Tidsramme: 4 Months

During each assessment session, occupational therapists measured patients' functions with the KF-NAP, Functional Independence Measure (FIM™) and Barthel Index (BI)

4 Months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studiestol: Fernando Vargas Torgal, MD, FSI, Fundacion Salud Infantil Elxe (Alcante)

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2017

Primær færdiggørelse (Faktiske)

1. oktober 2017

Studieafslutning (Faktiske)

28. december 2017

Datoer for studieregistrering

Først indsendt

14. september 2017

Først indsendt, der opfyldte QC-kriterier

10. april 2023

Først opslået (Faktiske)

24. april 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RefEpTDCs

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

biogdata4brain.com is the database where our foundation recorda all the clinical data of our assays

IPD-delingstidsramme

4 Months

IPD-delingsadgangskriterier

login and password previous registration in neuroterapias.es

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .